NCT04131556View on ClinicalTrials.gov

A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants

PHASE1TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 25, 2019

Primary Completion Date

January 6, 2020

Study Completion Date

January 6, 2020

Conditions
Healthy Volunteers
Interventions
DRUG

Maribavir

Participants in both part 1 and part 2 of the study will receive maribavir tablet or suspension orally depending upon the treatment sequence allocation for a total of 7 and 10 days respectively.

Trial Locations (1)

33014

Clinical Pharmacology of Miami, Llc, Miami

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY

NCT04131556 - A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants | Biotech Hunter | Biotech Hunter